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ABSTRACT
Graft-versus-host disease (GVHD) accounts for increased morbidity and mortality after HLA-identical unre-
lated hematopoietic cell transplantation (HCT). To test the hypothesis that the major histocompatibility
complex (MHC) encodes functional variation other than the classical HLA genes, we measured risks associated
with donor-recipient MHC microsatellite (Msat) marker mismatching in 819 HCT recipients and their
HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors. Suggestive trends of association with
transplant outcome were observed for 5 Msats. Donor-recipient mismatching for the extended class I D6S105,
class III D6S2787, and class II D6S2749 markers was each associated with an increased risk of death (hazard
ratio, 1.32; 95% confidence interval, 1.02-1.71; P  .03; hazard ratio, 1.26; 95% confidence interval, 1.03-1.53;
P  .02; hazard ratio, 1.37; 95% confidence interval, 1.08-1.72; P  .007, respectively) whereas mismatching
for the class I D6S2811 marker was associated with a decreased risk of death (hazard ratio, 0.80; 95%
confidence interval, 0.66-0.98; P  .03). Mismatching for the class I D6S265 marker was associated with a
decreased risk of grades III-IV acute GVHD (odds ratio, 0.67; 95% confidence interval, 0.45-0.98; P  .04).
These results suggest that Msats may be informative for mapping MHC-resident genetic variation of clinical
importance in HCT.
© 2007 American Society for Blood and Marrow Transplantation
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lNTRODUCTION
Despite matching of donor and recipient HLA-A,
B, -C, -DRB1, and -DQB1 alleles, HLA-identical
ransplant recipients suffer from life-threatening com-
lications after unrelated hematopoietic cell trans-
lantation (HCT) [1-3]. HLA genes are encoded
ithin the gene-dense major histocompatibility complexMHC) region, residence for over 400 genes, many of 7
86hich have immune-related function [4-6]. The MHC
egion has been the subject of intense study due to its
ivotal role as the “transplantation barrier” and its asso-
iation of HLA genes with disease susceptibility [4]. The
dentiﬁcation of non-HLA MHC loci among the hun-
reds of candidate genes presents a methodologic chal-
enge, because complete sequence characterization of the
.6-Mb extended MHC region is prohibitive.
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MHC Microsatellites in Transplantation 987Recent studies of MHC microsatellite (Msat)
arkers have furthered the understanding of the ge-
etic organization and the extent and patterns of link-
ge disequilibrium (LD) within the HLA region
7-11]. MHC Msats are not themselves functional;
owever, their inherent polymorphism and LD with
LA loci make them a robust disease-mapping tool in
utoimmune and infectious disease models and in
CT [8,12-14]. Broad application of Msats has also
een proposed as an efﬁcient means for screening
otential unrelated donors for HCT [15-17] (http://
ww.euromado.org/).
We hypothesized that unidentiﬁed donor-recipi-
nt variation could be associated with reduced or in-
reased risks of graft-versus-host disease (GVHD),
elapse, or death after HLA-matched unrelated donor
CT, and we used Msats to query the MHC for new
ransplantation determinants. We report the ﬁndings
rom a large dataset of the International Histocom-
atibility Working Group (IHWG) in HCT, a con-
ortium of international transplant centers and histo-
ompatibility laboratories (http://www.ihwg.org).
ATERIALS AND METHODS
tudy Population
A total of 819 transplants met the following study
riteria: (1) ﬁrst transplantation from an HLA-A, -B,
C, -DRB1, or -DQB1 allele-matched unrelated do-
or; (2) myeloablative conditioning regimen; (3) mar-
ow (T cell replete or T cell depleted) or peripheral
lood stem cell (PBSC) HCT for the treatment of
cute lymphoblastic leukemia (ALL), acute myeloid
eukemia (AML), chronic myeloid leukemia (CML),
r myelodysplastic syndrome (MDS); (4) availability
f complete clinical outcome and retrospective
igh-resolution HLA-A, -B, -C, -DRB1, and
DQB1 typing data (Table 1). The following con-
ributors provided clinical samples and data to this
tudy: National Marrow Donor Program (NMDP)
nd Center for International Blood and Marrow
ransplant Research (n  384), Australian Bone
arrow Donor Registry (n  27), the Société
rançaise de Greffe de Moelle (SFGM), and the
egistre France Greffe de Moelle (RFGM) (n 
8), Netherlands Stem Cell Transplantation Regis-
ry (Typhon) (n  16), and Fred Hutchinson Can-
er Research Center (FHCRC) (n  314).
All research samples and data were collected ac-
ording to institutional review board (IRB)-approved
uidelines and protocols of each of the participating
nstitutions. For samples from NMDP, all surviving
ecipients included in this analysis were retrospec-
ively contacted and provided informed consent for
articipation in the NMDP research program. In-
ormed consent was waived by the NMDP IRB for all -eceased recipients. To address bias introduced by
nclusion of only a proportion of surviving patients
those who consented) but all deceased recipients, a
ample of deceased patients was selected using a
eighted randomized scheme that adjusts for overrep-
esentation of deceased patients in the consented
ohort.
The self-described patient and donor racial back-
rounds were as follows: North American and Euro-
ean Caucasian 89% and 71%; Hispanic 1.7% and
.1%; Black 1.0% and 0.7%; Asian 0.6% and 0.2%;
ative American 0.2% and 0.6%; other or unknown
.4% and 26%.
enotyping of HLA and Microsatellites
Genotyping of donor-recipient HLA-A, -B, -C,
DRB1, -DRB3, -DRB4, -DRB5, -DQA1, -DQB1,
able 1. Characteristics of Study Population, n  819
onor-Recipient Pairs
edian recipient age, y (range) 36.2 (1-62.8)
ear of transplantation, n (%)
1985-1990 76 (9.3%)
1991-1996 484 (59.1%)
1997-2003 259 (31.6%)
ecipient/donor gender, n (%)
Male/male 331 (40.4%)
Male/female 153 (18.7%)
Female/male 173 (21.1%)
Female/female 156 (19.0%)
Unknown 6 (0.7%)
iagnosis/disease severity,* n (%)/n
ALL/high risk, intermediate risk 62 (7.6%)/12, 50
AML/high risk, intermediate risk 183 (22.3%)/77, 106
CML/high risk, intermediate risk,
low risk 544 (66.4%)/23, 122, 399
MDS/high risk, intermediate risk 30 (3.7%)/15, 15
ecipient/donor CMV serology, n (%)
Positive/positive 129 (15.8%)
Positive/negative 207 (25.3%)
Negative/positive 102 (12.5%)
Negative/negative 281 (34.3%)
Unknown 100 (12.2%)
onditioning regimen, n (%)
Total-body irradiation containing 726 (88.6%)
Other 93 (11.4%)
ource of cells, n (%)
Bone marrow 738 (90.1%)
Peripheral blood stem cells 13 (1.6%)
Unknown 68 (8.3%)
cell depletion, n (%)
Yes 93 (11.4%)
No 726 (88.6%)
LL indicates acute lymphoblastic leukemia; AML, acute myeloid
leukemia; CML, chronic myeloid leukemia; MDS, myelodys-
plastic syndrome; CMV, cytomegalovirus.
Disease severity categories were deﬁned as low risk (CML chronic
phase), intermediate risk (CML accelerated phase or blast crisis/
remission; acute leukemia transplanted in remission; MDS-
refractory anemia); or high risk (blast crisis CML; acute leuke-
mia transplanted in relapse; MDS other than refractory anemia).DPA1, and -DPB1 alleles was performed by direct
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M. Malkki et al.988equencing and PCR-sequence speciﬁc oligonucleotide
robe (SSOP) methods using 13th IHWG workshop or
ocally designed protocols [18-20] (http://ihwg.org/
manual/TMcontents, http://bioinformatics.nmdp.org/
LA/HR/hr_methods_idx.html).
The following Msats were studied: D6S276,
6S105, D6S510, D6S265, D6S2811, D6S2810,
6S2787, D6S273, D6S2876, D6S2874, D6S2749,
nd D6S291 (Figure 1, Table 2). Msat genotyping of
he samples from the Australian Bone Marrow Donor
egistry, NMDP, Typhon, and FHCRC was per-
ormed by the IHWG HCT Coordinating Labora-
ory (FHCRC, Seattle, WA), and samples from the
FGM and RFGM was genotyped by 4 laboratories
FRABET, FRABOI, FRABIG, and FRAMYE) as pre-
iously described (http://www.ihwg.org/components/
ctr.htm). A DNA reference panel containing 50 DNAs
13th IHWG Core Cell and Gene Bank, www.ihwg.org/
ellbank/) was typed as a quality control. This reference
anel data was used to create an IHWG Msat dictionary,
hich normalizes Msat alleles to a common nomencla-
ure, thus allowing comparison of data from laboratories
sing different typing platforms [21]. Both the recipient
nd their corresponding donor sample were included in
he same Msat genotyping experiment to avoid possible
xperiment-to-experiment variation that could affect the
coring of the Msat match status between recipient and
onor. Each genotyping experiment also included 4 to 6
reviously typed IHWG reference panel DNAs as qual-
ty control for Msat allele assignments. Msat alleles were
eﬁned according to the base pair (bp) sizes of the am-
igure 1. Physical map of the MHC region and the location of M
DRB1, -DRB3, -DRB4, -DRB5, -DQA1, -DQB1, -DPA1, -DPB
entromere on chromosome 6p21.3. Coordinates refer to National
lm.nih.gov/mapview/maps.cgi?taxid9606&chr6, www.ncbi.nlm
LA-DPB1 is drawn to scale. The genetic distance is 3.6 Mb bet
LA-A (double hatch), and 3.2 Mb between HLA-DPB1 and D6
rovided in Table 2.liﬁed Msat fragment.ssessment of Hardy-Weinberg
quilibrium (HWE)
The principle of HWE is the relationship between
he frequencies of alleles and the genotypes of a pop-
kers used in this study. Position of the Msats and HLA-A, -B, -C,
CA, MICB, and TNF are listed in map order from telomere to
r for Bioinformatics (NCBI) chromosome 6 build 36.2 (www.ncbi.
v/sites/entrez?dbunists). The 3.1-Mb region between HLA-A to
6S276 and D6S105 (single hatch), 2.1 Mb between D6S105 and
triple hatch). The kilobase (kb) pair distance between markers is
able 2. Microsatellite Markers Evaluated in the Study Population
Marker* Alias
Distance to
Next Marker
(kb)
Number of
Transplant Pairs
Genotyped
6S276 3600 814
6S105 2100 813
HLA-A 31 819
6S510 78 818
6S265 1200 813
HLA-C 23 819
6S2811 HLABCCA2 63 817
HLA-B 27 819
6S2810 MIB 228 734
6S2787 BAT2CA 106 817
6S273 863 810
HLA-DRB1 81 819
HLA-DQB1 42 819
6S2876 G51152 149 818
6S2874 TAP1CA 123 818
6S2749 RING3CA 101 818
HLA-DPB1 3200 809
6S291 810
f the 819 pairs in this dataset, the genotyping for HLA-DRB3,
DRB4, or DRB5 loci was performed for 612 pairs and the
genotyping for DQA1 and DPA1 loci for 576 pairs Out of the
612 pairs, DRB3 gene was present in 401 pairs, DRB4 in 327
pairs and DRB5 in 197 pairs.
Markers are listed in the order of their mapping on chromosome
6p21.3. HLA loci are included for the purpose of orientationsat mar
1, MI
Cente
.nih.go
ween D
S291 (with respect to the Msats studied.
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MHC Microsatellites in Transplantation 989lation [22]. Inherent in HWE is the assumption that
sufﬁciently large population has random mating and
o migration, mutation, or selection. Under these
onditions, genotypes are constant and their frequen-
ies are in genetic equilibrium. Violation of Hardy
einberg assumptions cause deviation from expecta-
ion, and can arise from nonrandom mating, genetic
rift, mutation, or natural selection. In studies of ge-
etic association, technical failure of allele genotyping
eading to excess homozygosity or heterozygosity may
lso lead to violation of HWE [23]. In the current
tudy, observed HLA-A, -B, -C, -DRB1, -DQB1, and
sat genotype frequencies in Caucasians were tested
or HWE as previously described [11].
tatistical Analysis
Relapse was deﬁned by morphologic or cytoge-
etic evidence of disease in the peripheral blood or
one marrow as previously described [2,3]. Acute
VHD (aGVHD) was deﬁned as previously described
2,3,24]. For the GVHD analysis, Msat mismatching
as deﬁned as the presence of recipient Msat alleles
ot shared by the donor. For relapse and survival
nalyses, a pair was mismatched if the recipient en-
oded a Msat allele not shared by the donor, and/or
he donor an allele not shared by the recipient.
Cox regression models were used to assess the
mpact of Msat mismatching on outcome and were ﬁt
or the time-to-event endpoints of relapse and overall
urvival. Logistic regression models were used to ex-
mine the association of mismatching with grades
II-IV aGVHD. All models were adjusted for patient
ge, disease severity, use of total-body irradiation
TBI), use of T cell depletion, number of mismatches
t Msat loci other than the Msat of interest, and
umber of HLA-DPB1 disparities.
To test the hypothesis that the total number of
ismatched Msats between HLA-A and HLA-DPB1
as associated with outcome, the number of mis-
atched Msats was modeled as a continuous linear
ariable (a value from 0 to 11). Treating the number of
ismatched Msats in this way assumes that all Msats
ontribute equally to outcome, and that any increase
n a speciﬁed number of mismatches is associated with
he same change in hazard (or odds) of failure. By
rouping the Msats according to their location within
lass I (D6S510, D6S265, D6S2810), class III
D6S2787, D6S273), or class II (D6S2876, D6S2874,
6S2749), the assumption that mismatching at each
sat contributes equally to outcome was relaxed to
ssume that each Msat within a region contributes
qually, but not necessarily the same from region to
egion. The number of mismatched Msats within a
egion was modeled as a continuous linear variable (a
alue of 0-3 for class I, 0-2 for class III and 0-3 for
lass II). The D6S2810 was excluded from these anal- mses because 10% of the study population was not
enotyped for this marker.
Two-sided P-values from the regression models
ere obtained from the Wald test. Due to the unknown
evel of correlation between mismatching at the various
sats and the high degree of association between clinical
utcomes, no adjustments were made for multiple com-
arisons. Therefore, P-values between .01 and .05
hould be considered as suggestive, rather than conclu-
ive, evidence of a true difference.
ESULTS
WE of Msats
The most polymorphic Msat marker was D6S2811
23 alleles) and the least polymorphic were D6S291
nd D6S2749 (11 alleles each) (data not shown). The
requency of Msat alleles did not differ signiﬁcantly
etween recipient and donor samples.
Deviation from HWE was tested for each HLA
ocus and Msat marker among patients and among
onors because the pairs were matched for HLA loci,
nd therefore not independent. No HWE deviation
as observed for HLA loci. Deviation from HWE was
etected for D6S2810 and D6S276 in both donor and
atient samples and for D6S2811 in patients and
6S2749 in donors. Accordingly, we investigated the
ontributions of homozygosity and heterozygosity at
6S276, D6S2810, D6S2811, and D62749. Only
6S276 demonstrated excess homozygosity in pa-
ient and donor samples (D6S276*141,141 was ob-
erved 14 times and expected 6.94 times in donor
amples; it was observed 15 times and expected 6.84
imes in patient samples). The majority of the Msats
hat deviated from HWE included only a small
ubset of combination of alleles that resulted in
ncreased (donor D6S2810*277,281 [observed 14/
xpected 7.63]; patient D6S276*141,143 [observed
5/expected 6.84]) or decreased heterozygosity (donor
6S2749*231,233 [observed 22/expected 35.83]; do-
or D6S276*141,143 [observed 26/expected 41.64];
onor D6S2810*279,281 [observed 3/expected 12.30];
atient D6S2810*281:285 [observed 3/expected 9.78];
atient D6S2811*108,110 [observed 1/expected 7.60]).
mong the heterozygous allele combinations that de-
iated from HWE, several allele pairs differed only by
dinucleotide repeat (2 bp). To investigate the pos-
ibility that deviation was caused by technical error,
uality DNA controls were retyped and the raw geno-
yping data was reanalyzed for 90% of the samples; no
bvious technical problems such as failure to amplify a
econd allele were identiﬁed. For this reason none of
hese Msats were removed from data analysis.
onor-Recipient Msat Matching
The frequency of donor-recipient Msat mis-
atching among the 819 HLA-A, -B, -C, -DRB1, or
-
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M. Malkki et al.990DQB1 matched pairs ranged from 9% (D6S2876) to
1% (D6S276) (Figure 2).
LD patterns with HLA loci and the Msats in-
luded in this study have been previously described
11]. A higher degree of LD was observed with Msat
arkers that map in close proximity to the classical
LA loci. When the 6 Msats that reside between
lassical HLA-A and -DRB1 loci were evaluated for
ismatching (D6S510, D6S265, D6S2811, D6S2810,
6S2787, and D6S273), 157 pairs (22.3%) were
atched for all 6 Msat loci; the remaining 537 pairs
ere mismatched for 1 (17.8%), 2 (21.3%), 3 (15.1%),
(9.8%), or 5 or more (13.8%) Msats.
rades III-IV aGVHD
A trend for lower probability of grades III-IV
GVHD was observed with mismatching for the
6S265 class I marker (odds ratio [OR], 0.67; 95%
onﬁdence interval [CI], 0.45-0.98; P. 04) (Table 3).
o statistically signiﬁcant association between the to-
al number of mismatched Msats (regardless of the
egion in which the Msat resides) and the probability
f grades III-IV aGVHD was observed (P  .60).
hen Msats were grouped according to their location
ithin class I, class III, or class II, there was a sugges-
ion of an association between the number of class I
ismatched Msats and the probability of aGVHD,
ith less aGVHD associated with increasing number
f mismatches (P  .06). The number of mismatched
lass III or class II Msats were not associated with the
robability of aGVHD (P  .65 and P  .38, respec-
ively). Among the 11 patients (7 low-risk, 2 high-risk,
igure 2. Rate of mismatching among HLA-A, -B, -C, -DRB1, and
oci are included for the purpose of orientation with respect to the M
ll 12 Msats, 109 (13%) for all Msats except D6S2810, and 6 pairs
1.6%) were matched for all 12 Msat loci; the remaining 693 pairs w
86.8%) Msats.nd 2 intermediate-risk recipients) who were com- .letely matched with their respective donors for all 12
sats, 3 developed grade III aGVHD (but were alive
t last contact), 4 died (day 110, 126, 154, 245) after
CT and none relapsed.
elapse
No statistically signiﬁcant or suggestive associa-
ions between Msat mismatching and relapse were
bserved. There was no statistically signiﬁcant associ-
tion between the number of mismatched Msats (re-
ardless of the location of Msat) and the hazard of
elapse (P  .18) or between the number of class I,
lass II, or class III Msat mismatches and the hazard of
elapse (P  .43, P  .29, P  .68 for class I, class III,
nd class II, respectively).
verall Mortality
There was a trend for a lower risk of death with
ismatching for D6S2811 (hazard ratio [HR], 0.80;
5% CI, 0.66-0.98; P .03) and a higher risk of death
ith mismatching for D6S105 (HR, 1.32; 95% CI,
.02-1.71; P  .03), D6S2787 (HR, 1.26; 95% CI,
.04-1.53; P  .02), and D6S2749 (HR, 1.37; 95%
I, 1.09-1.72; P  .007) (Table 3).
The hazard of mortality increased as the total
umber of mismatched Msats increased regardless of
he location of the Msat within the MHC (P  .01).
ategorizing the number of Msat mismatches (arbi-
rarily) as 0-1, 2-3, 4-8, and 9-11, the hazard of mor-
ality increased for each of these categories compared
o the group with 0-1 mismatched Msats (HRs 1.25 [P
matched donor-recipient study pairs for MHC region Msats. HLA
tudied. Of the 819 study pairs, 704 (86%) were each genotyped for
or 10 or fewer Msats because of PCR failure. Of the 704 pairs, 11
ismatched for 1 (1.2%), 2 (2.1%), 3 (2.1%), 4 (6.2%), or 5 or more-DQB1
sats s
(3%) f
ere m53], 1.71 [P  .10], and 2.10 [P  .03], respectively).
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MHC Microsatellites in Transplantation 991When Msats were grouped according to their lo-
ation within class I, class III, or class II, the hazard of
ortality increased with increasing number of mis-
atched class III and class II Msats (P  .008 and P 
01, respectively), but not within class I Msats (P  .10).
ISCUSSION
aGVHD may arise when donor T cells recognize
ifferences in recipient HLA. Alternatively, decreased
VHD risk has been observed when there is release of
nhibition mediated by donor natural killer immuno-
lobulin-like receptors (KIR), either through donor-
ecipient ligand mismatching [25] or through absence
f recipient ligand [26]. In the current study, we tested
he hypothesis that undetected MHC variation among
LA matched transplants may inﬂuence the risk of
VHD, leading to either increased or decreased risk.
o this end, we used Msat markers as a gene-mapping
ool. Although Msats themselves are not functional,
hey may be in LD with the putative at-risk gene(s).
ur results demonstrate that differences between do-
or and recipient Msat alleles inﬂuence GVHD risk
nd survival. Mapping of candidate genes will be fa-
able 3. Adjusted Effect of Microsatellite (Msat) Mismatching on Prob
ematopoietic Cell Transplantation from HLA-identical Unrelated Don
Prop
Clinical Endpoint Msat Msat Match
rades III-IV acute GVHD D6S276 48/143 (34
D6S105 64/217 (30
D6S510 192/600 (32
D6S265 200/601 (33
D6S2811 180/544 (33
D6S2810 171/535 (32
D6S2787 177/545 (33
D6S273 153/512 (30
D6S2876 236/739 (32
D6S2874 155/496 (31
D6S2749 72/266 (27
D6S291 66/203 (33
verall mortality D6S276 40/76 (53
D6S105 79/150 (53
D6S510 351/576 (61
D6S265 358/581 (62
D6S2811 339/537 (63
D6S2810 336/530 (63
D6S2787 294/511 (58
D6S273 272/460 (59
D6S2876 450/741 (61
D6S2874 219/366 (60
D6S2749 106/194 (55
D6S291 77/127 (61
VHD indicates graft-versus-host disease.
Adjusted for patient age, disease severity, use of total body irradia
marker of interest and number of HLA-DPB1 disparities.
Odds ratio (OR; acute GVHD) and hazard ratio (HR; mortality) m
in interest; CI, conﬁdence interval.ilitated in the future with the availability of a ﬁne sHC map [5,6,27,28]. Dissection of the underlying
ellular mechanisms that account for susceptibility to
r protection against GVHD remains an important
esearch question in the future.
In genetic association studies, it is customary to
est the genotyping data for departures from HWE, as
eviations could help to identify genotyping errors
22,23]. Deviation from HWE for a subset of markers
ould also arise from chance alone [22,23]. In the
urrent study, 4 Msats were found to deviate from
WE. Of these, D6S276 had an excess of homozy-
otes for 1 of the alleles, and D6S2810, D6S2749, and
6S2811 showed either increased or decreased het-
rozygosity of certain genotype combinations com-
ared to their expectations under HWE. Reevaluation
f the raw electrophoresis data indicated no obvious
echnical explanation for any of the deviating Msats.
e interpret these ﬁndings as potentially indicative of
highly selected population of HLA matched trans-
lant recipients and donors.
The associations observed in this study will re-
uire validation in independent populations because
he number of polymorphic Msat loci increases the
otential that some of the statistically signiﬁcant as-
f Grades III-IV Acute GVHD and Overall Mortality after
(%) of Events
Msat Mismatched OR or HR (95% CI)† P
204/657 (31) 0.83 (0.56-1.24) .37
188/583 (32) 1.07 (0.76-1.52) .69
61/204 (30) 0.92 (0.64-1.33) .67
52/199 (26) 0.67 (0.45-0.98) .04
73/259 (28) 0.76 (0.54-1.07) .11
59/187 (32) 0.94 (0.65-1.35) .74
75/258 (29) 0.83 (0.59-1.17) .29
97/284 (34) 1.23 (0.89-1.71) .21
17/65 (26) 0.71 (0.39-1.31) .28
98/308 (32) 1.00 (0.73-1.38) .99
181/538 (34) 1.36 (0.97-1.91) .08
186/593 (31) 0.99 (0.70-1.40) .94
458/738 (62) 1.38 (0.98-1.94) .07
417/663 (63) 1.32 (1.02-1.71) .03
151/242 (62) 1.00 (0.82-1.47) .92
139/232 (60) 0.86 (0.70-1.07) .19
162/280 (58) 0.80 (0.66-0.98) .03
113/204 (55) 0.81 (0.65-1.00) .06
206/306 (67) 1.26 (1.03-1.53) .02
225/350 (64) 1.18 (0.98-1.43) .08
51/77 (66) 0.99 (0.72-1.35) .95
282/452 (62) 1.17 (0.97-1.41) .10
395/624 (63) 1.37 (1.08-1.72) .007
419/683 (61) 1.13 (0.87-1.46) .39
se of T cell depletion, number of mismatches at Msat other than
risks associated with Msat mismatching relative to Msat matchingability o
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M. Malkki et al.992LA-A, -B, -C, -DRB1, and -DQB1 mismatching did
ot contribute to the risks in this study population;
owever, immune response gene variation, chromo-
ome 22 Msat, and KIR/HLA interactions are well
ecognized [25,26,29-40]. Because these genes are not
ncoded on chromosome 6 (with the exception of
umor necrosis factor [TNF] gene), their allele fre-
uencies are expected to be similar among the Msat
ismatched groups within the study population.
ther MHC region genes such as HLA-DPB1 have
een shown to be associated with GVHD, rejection,
nd mortality after unrelated HCT [19,41-44]. In the
urrent study, mismatching at HLA-DPB1 was in-
luded in the regression models. Moreover, HLA-
PB1 mismatching did not have a demonstrable ef-
ect on the associations of Msat mismatching with
utcome. Out of the 113 HLA-DPB1 matched pairs
hat had corresponding data for HLA-DPA1 locus,
here were only 10 (9%) HLA-DPA1 mismatched pairs.
ismatching in HLA-DRB3, -DRB4, -DRB5, and
DQA1 was minimal (6.5%, 3.7%, 1%, and 0.5%, re-
pectively) (data not shown). Although genotyping data
or HLA-DRB3, -DRB4, -DRB5, -DQA1, and -DPA1
ere not available for all transplant pairs (Table 2), the
ontribution of these loci to clinical outcome is likely
ery small due to the high LD, and consequently, low
ismatch frequency [45-47].
HLA-A2-positive patients may be at increased risk
f aGVHD after related donor transplantation be-
ause of HA-1 and HA-2 minor histocompatibility
ntigens [48]. In our study population, HLA-A2 was
resent at equal frequencies in both Msat-matched
nd Msat-mismatched pairs for all Msats with the
xception of D6S265 and D6S510. For both D6S265
nd D6S510, HLA-A2 was present at 74% frequency
n Msat mismatched pairs and at 39% frequency in
sat matched pairs. Despite the skewing of the
LA-A2 proportions, the rate of GVHD among the
6S265 mismatched pairs was 25% in HLA-A2-pos-
tive pairs and 26% in HLA-A2-negative pairs. Hence,
t is unlikely that HLA-A2 affected the observed as-
ociation of D6S265 mismatching with GVHD risk.
Our observations suggest that HLA-matched un-
elated donors and recipients may have Msat-linked
enetic variation outside of the classical HLA loci, and
hat this variation may inﬂuence the risks of aGVHD
nd mortality. Although a dense map of the MHC
5,6,27,28] is currently available, LD between these
ingle nucleotide polymorphisms and Msats is un-
nown. In the current study Msat marker mismatch-
ng was deﬁned as any detectable difference between
he recipient and donor. Whether Msat alleles that
iffer by 2 bp or more are linked to the same func-
ional gene is not known, and remains an important
esearch question. It was not our intention to examine
sat-HLA haplotype associations to clinical outcomeecause of the reported inaccuracies of the population atatistics for individual haplotype inference [49].
hese analyses will be feasible in the future when new
aboratory techniques are available to deﬁne Msat
aplotypes across the MHC [50].
The current study found suggestive associations
ith transplant outcome in 4 regions: D6S105 in the
xtended class I, D6S265 to D6S2811 in class I,
6S2787 in class III, and D6S2749 in class II. Al-
hough no data is currently available on the LD be-
ween D6S2811 and MICA or MICB genes, a poten-
ial role for MIC is intriguing. MIC-A and MIC-B
enes map 18 kb and 113 kb centromeric to D6S2811.
IC gene products serve as ligands for the NKG2D
ctivating receptor on NK cells, CD8 T cells and
amma/delta T cells [51]. Donor-recipient matching
or the class I region inclusive of MIC has been asso-
iated with improved survival after unrelated HCT
52]. Another interesting gene cluster, TNF, is located
8 kb telomeric to D6S2787. The polymorphic TNF
lpha and beta genes have been implicated in GVHD
nd transplant-related mortality [30,31,36-39]. Fi-
ally, several genes surrounding D6S265, D6S2749,
nd D6S105 markers have been described [5,6,53,54];
owever, any putative role in transplantation is spec-
lative at this time.
GVHD is a complex disease that is the conse-
uence of synergistic effects of multiple genes. To
ddress whether additive effects of MHC region poly-
orphisms contributed to the risks of GVHD, re-
apse, or mortality, we analyzed the Msats according
o the total number of mismatched Msats, and to the
egion within the MHC. The analysis of the cumula-
ive effect of Msat mismatching revealed a suggestive
ssociation of increasing numbers of class III (D6S273
nd D6S2787) or class II (D6S2876, D6S2874, and
6S2749) mismatched Msats with increased hazard of
ortality. The majority of the class III and class II
ismatches included D6S2787 (72%) and D6S2749
82%) (data not shown), each of which was associated
ith increased risk of death (Table 3). The cumulative
ffect of class III or II mismatching with outcome
ight be explained by a higher proportion of mis-
atching for D6S2787 or D6S2749, respectively,
ompared to the other Msats within class III (D6S273)
nd II (D6S2876 and D6S2874) regions. Alternatively,
hese other class III and class II Msats may be hitch-
iking with D6S2787 or D6S2749.
Four of the Msat markers (D6S273, D6S2810,
6S265, and D6S510) described herein were studied
y Li et al. [14]. The frequency of donor-recipient
atching for these loci was higher among Japanese
ransplant pairs than in our study population (64%,
9%, 81%, and 97% versus 57%, 72%, 71%, and
0%, respectively), possibly indicating more highly
onserved haplotypes within Japanese population
www.hapmap.org). No statistically signiﬁcant associ-
tions between mismatching for any of the 13 Msats
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MHC Microsatellites in Transplantation 993nd aGVHD, chronic GVHD (cGVHD), survival, or
elapse were uncovered by Li et al.; however, match-
ng for the class III TNFd marker among recipients
ith grades III-IV aGVHD was associated with de-
reased survival [14]. Whether differences in Japanese
nd Caucasian MHC haplotypes (www.hapmap.org)
an explain the associations to transplantation out-
ome remain to be determined in future studies. The
urrent study provides the impetus for ﬁne mapping of
HC sequence variation in ethnically diverse trans-
lant populations.
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